This final conversation focuses on conference presentations on Determinants of MASH Health and the Healthy Livers, Healthy Lives program, and what panelists anticipate for #TLM2025.
This conversation covers the likely role of FGF-21 agents in future MASH therapy and discusses positive messages from the “FDA Corner” session.
This conversation starts by asking whether approval of two drugs for use without biopsy will challenge MASH trial recruitment and goes on to look at recent studies discussing patient genotyping and clustering.
In the first conversation of our review of #TLM2024, panelists share general impressions and discuss the ESSENCE trial, semaglutide’s Phase 3 trial demonstrating regression of fibrosis.
A diverse group of MASLD/MASH stakeholders joins Jörn Schattenberg and Roger Green to discuss The Liver Meeting 2024 about key breakthroughs, explore emerging research on new therapies, and reflect on collaborative efforts that advance patient care and outcomes in the field.
Maru Rinella, corresponding author for the recent expert panel recommendations on resmetirom, joins the Surfers to discuss key points of the recommendations and the rationale behind them.
S5 E23 panelists Mike Betel and José WIllemse join Roger Green to review the three answers audience members sent for Season 5 Episode 23’s Question of the Week on Provider-Patient Communication.
In the second half of Roger Green’s interview with Global Liver Institute Vice President, Liver Programs Jeff McIntyre, Jeff discusses the implications of his key EASL Congress takeaways for GLI and other patient advocacy groups.
Global Liver Institute Vice President of Liver Programs Jeff McIntyre joins Roger Green to discuss what he considers key takeaways for GLI from EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key implications for his business from what he learned at EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key takeaways for his business from EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean and Global LIver Institute Vice President of Liver Programs Jeff McIntyre join Roger Green for 1:1 interviews exploring their key takeaways and strategic shifts resulting from the EASL Congress 2024, followed by a review of answers to a previous Question of the Week.
Roger Green speaks with SurfingMASH co-host and Tawazun Health Founder and Clinical Director Louise Campbell on the last day of the EASL Congress. Their conversation focuses on how practice patterns, guidelines and training might change over the next few years.
Roger Green speaks with Hepatology Key Opinion Leader and EASL Educational Councillor Sven Francque 90 minutes after the EASL Congress closed. The discussion covers Clinical Practice Guidelines, drug development and NITs.
Roger Green speaks with SurfingMASH co-host and Tawazun Health Founder and Clinical Director Louise Campbell on the last day of the EASL Congress. The discussion covers Clinical Practice Guidelines, drug development and NITs.
Roger Green speaks with SurfingMASH co-host and Tawazun Health Founder and Clinical Director Louise Campbell on the first day of the EASL Congress. The discussion includes the Patient Advocacy session co-chaired by Mike Betel and Shira Zelber-Sagi and several other presentations she attended.
Roger Green speaks with Fatty Liver Alliance Founder and CEO Mike Betel on the day before the EASL Congress officially opens. The discussion includes sessions Mike attended and one he co-chaired with Shira Zelber-Sagi, which is covered in Season 5 Episode 23.
Four panelists from the EASL Congress session on “Patient Experiences in Clinical Settings” join Louise Campbell to how socioeconomic and psychological issues can affect the physician-patient dialogue.
Four panelists from the EASL Congress session on “Patient Experiences in Clinical Settings” join Louise Campbell to discuss ways to improve information sharing in the physician-patient dialogue.
Four panelists from the EASL Congress session on “Patient Experiences in Clinical Settings” join Louise Campbell to discuss some dynamics of the physician-patient dialogue.
This conversation with Louise Campbell and four panelists from the EASL Congress session titled “Patient Experiences in Clinical Settings” provides an overview of issues in physician-patient communication.
Louise Campbell leads a discussion about challenges in provider-patient communication with Shira Zelber-Sagi and Mike Betel, who chaired a session on this topic at the EASL Congress 2024, and Tom Marjot and Jose Willemse, who were panelists for the discussion.
Jeff Lazarus and the Surfers discuss the upcoming UN event for “Healthy Livers, Healthy Lives,” focusing on MASLD awareness. They explore challenges in educating policymakers, strategies for highlighting MASLD’s impact, and ways listeners can support the initiative.
Healthy Livers, Healthy Lives Chair Jeff Lazarus and the Surfers discuss the value of the updated EASL/EASD/EASO MASLD clinical practice guidelines and explore the role of Big Data in early MASLD screening.
Healthy Livers, Healthy Lives Chair Jeff Lazarus and the Surfers discuss some specific challenges in building global MASLD policy and some local successes.
Healthy Livers, Healthy Lives’ Chair Jeff Lazarus shares with the Surfers the importance of political will in building a consensus for global MASLD public health policy.
In this opening conversation, Healthy LIvers, Healthy Lives Chair Jeff Lazarus discusses the goals of the coalition and two initiative to increase early screening.
Jeff Lazarus, Chair of Healthy Livers, Healthy Lives, joins the Surfers to discuss this global SLD Public Health coalition. and the role of “top-down” solutions.
This week’s vault conversation looks back 17 months to the publication of revised AASLD Practice Guidance.
In this closing conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi and podcast co-hosts Louise Campbell and Roger Green consider what the guidelines might foretell in changes in provider education, structure of patient visits and treatment in less affluent or medically advanced countries.
For most of this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi discuss key issues related to pharmacology and prescribing choices. At the end, the focus shifts to the guidelines’ overall benefits and some new kinds of education they call for.
In this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi discuss some of the guidelines’ key goals and issues surrounding the screening, diagnosis and management of MASLD patients.
In this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi explain how the guidelines process benefitted from the close collaboration between EASL, EASD, and EASO.
Two of the co-authors of the upgraded MASLD Clinical Practice Guidelines (CPG), Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the guidelines.
Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASDand EASO.
In this conversation from EASL Congress 2023, Stephen Harrison, Jörn Schattenberg and Roger Green discuss the future roles of FGF-21s and incretin agonists in what was then known as NASH and NAFLD therapy.
This conversation covers some of the other major drug development stories from the EASL Congress 2024, with special focus on denifenstat, ION-224 and TAK-227, plus a look at the SPECIAL study on bariatric surgery and cirrhosis.
This conversation focuses on the role FGF-21s will play in long-term advanced fibrosis treatment: induction or long-term therapy?
This conversation explores issues regarding incretin agonists and discusses results from the efruxiermin late-breaker at the EASL Congress 2024.
This conversation focuses on the tirzepatide late-breaker at the EASL Congress 2024 and broadens into a discussion of the other “Twin-cretins,” all of which are GLP-glucagon combinations.
This conversation from EASL Congress 2024 discusses some of the new research on resmetirom.
Naim Alkhouri and Mazen Noureddin join co-hosts Jörn Schattenberg and Roger Green to discuss the major drug development stories from the EASL Congress 2024.
Roger Green conducts 1:1 interviews with Mike Betel, Louise Campbell and Sven Francque while they are at the EASL Congress 2024, discussing key issues related to MASLD
This final conversation focus on what Sober Livers leaders Jenn Jones and Beth Lehman hope listeners will take from this discussion and ways they can help HOPE.
In this conversation, Society for Sober Livers leaders Jenn Jones and Beth Lehman discuss their plans for the future of HOPE.
Roger Green asks Sober Livers leaders Jenn Jones and Beth Lehman questions about services and future plans for HOPE, their unique support program for patients who have harmed themselves through ALD.
In this conversation, Roger Green asks why ALD patients who have harmed themselves through drinking will benefit from a unique support organization like HOPE.
Sober Livers Founder/Visionary Jenn Jones and Principal Strategic Advisor Beth Lehman join Roger Green to discuss HOPE, a unique, multi-element support program for people who have harmed their bodies through ALD.
Roger Green is joined by Sober Livers Founder/Visionary Jenn Jones and Principal Strategic Advisor Beth Lehman to discuss HOPE, (Healing Others with Peers and Education), a support program launching June 11 for people who have harmed their bodies through ALD and its consequences.
As the conversation wraps up, Jörn Schattenberg and Michelle Long discusses abstracts they will present at EASL Congress 2024, with Jörn focusing on new MASLD drug development and Michelle on an aggregation of studies sponsored by Novo Nordisk.
Two abstracts for the EASL Congress 2024 from Hannes Hagstrom’s team leads the group to focus on the future of Big Data within MASLD diagnosis and therapies.
This conversation starts when co-host Jörn Schattenberg joins our EASL Congress 20224 preview. The episode itself focuses on the future of hepatology along with other MASLD abstracts and presentations.
This conversation centers around two thoughts about the EASL Congress 2024 from Michelle Long.one on network value and the other on the reat benefit that comes from reviewing abstracts in advance.
EASL Secretary General Aleksander Krag offers his vision for the EASL Congress 2024, after which Hannes Hagstrom shared some impressions.
EASL Secretary General Aleksander Krag and our other guests, Hannes Hagstrom and Michelle Long, join Jörn Schattenberg and Roger Green to discuss MASLD-related highlights of EASL Congress 2024.
This second conversation with Dimitar Tonev and Roger Green focus on some of the elements of Stephen’s personality that made him a role model for the entire community in Dimitar’s eyes.
Dimitar Tonev and Roger Green discuss Stephen Harrison’s role as a major innovator in the MASLD space, with Dimitar focusing largely on Stephen developing the first clinical trial site network.
Jörn Schattenberg, Donna Cryer and Roger Green continue their conversation of Stephen Harrison by discussing his consistent efforts to be sure the voices of patients and allied health providers were included in key conversations.
Donna Cryer, Jörn Schatenberg and Roger Green reflect on Stephen Harrison’s ability to bring together all the various elements of the MASLD community in pursuit of knowledge and a first approved drug.
In two separate conversations, Global Liver Institute Founder and CEO and industry executive and consultant hepatologist Dimitar Tonev share memories of Stephen Harrison with co-hosts Jörn Schattenberg and Roger Green.
From INCBCN 2023: Last year’s Barcelona context took a “deep dive” into NITs by exploring some early findings from the NAIL-NIT consortium.
This final conversation from #SLDThinkTank 2024 start with the question, “Next year?” Two key foci emerge: broadening the set of groups in the meeting and focusing more broadly on the concept of preventive hepatology.
This conversation focuses largely on system preparedness and ways to improve scanners and other screening devices. One key point: this becomes more feasible now that Rezdiffra has been approved.
Jeff Lazarus describes the meeting agenda and some of the anticipated outputs, after which other panelists discuss the broad range of issues this design produced.
SLD Think Tank 2024 co-hosts Jeff Lazarus and Jörn Schattenberg describe a highly innovative meeting design and participants Maja Thiele and Mike Betel sharing their reactions.
